Aug 11, 2020

John Dimos, CEO, Fountain Therapeutics describes their approach to the treatment of age-associated diseases and points out that there is a big difference between chronological and biological age. In the search for finding a way to intervene in the aging process, Fountain is taking a hypothesis-free approach and with the...

Aug 11, 2020

John Dimos, CEO, Fountain Therapeutics describes their approach to the treatment of age-associated diseases and points out that there is a big difference between chronological and biological age. In the search for finding a way to intervene in the aging process, Fountain is taking a hypothesis-free approach and with the...

Mar 6, 2019

Dr. Dan Alkon, President and Chief Scientific Officer, Neurotrope is an internationally recognized pioneer in research on brain based neural networks, the molecular basis of memory and degenerative brain disorders.  Neurotrope has seen very promising results in clinical trials with Bryostatin-1 with patients with...

Dec 4, 2018

Elad Kedar, CEO, Orasis discusses CSF-1, the company's corrective eye drop being developed for the treatment of presbyopia as an alternative to reading glasses.  Presbyopia, the inability to focus on near objects, is common after the age of 40 and affects more than 1.8 billion people worldwide.  While glasses have been...

Jan 24, 2018

Roma Patel MD, Chief Ophthalmologist for the Sacramento VA and assistant professor at the University of CA Davis emphasizes that there are treatments for delaying the full impact of glaucoma but that the condition needs to be found early.  Glaucoma is a silent disease that presents no early warning signs but can be...